FierceBiotech 4 mar 2026 Pfizer's oncology R&D strategy: Jeff Legos on speed, breadth and novel combinations
FierceBiotech 25 feb 2026 After gene therapy exit, Pfizer locks in global license for Beam gene editing candidate
Endpoints News 24 feb 2026 Pfizer buys China rights to Sciwind’s approved GLP-1 drug in metabolic push
Endpoints News 7 feb 2026 The Hims vs. Novo showdown; Pfizer’s monthly GLP-1 data; Q4 earnings roundup; and more
FierceBiotech 6 feb 2026 Pfizer-backed Priovant scores again with fast-rising brepocitinib in midstage study
BioPharma Dive 4 feb 2026 Earnings roundup: Amgen vs. FDA, Pfizer’s defense and Merck’s $70B-in-sales plan
FierceBiotech 4 feb 2026 Novo's CEO 'wishes Pfizer luck' with Metsera drug, but still seeks own monthly GLP-1
FierceBiotech 21 ene 2026 Pfizer CEO lays blame for US vaccine woes on RFK Jr.'s 'anti-science' stance: WSJ
BioPharma Dive 12 ene 2026 JPM26: US biotech’s ‘Sputnik moment,’ Pfizer’s obesity ambitions and Bristol Myers’ big year
FierceBiotech 9 ene 2026 Madrigal pays $50M for Pfizer MASH drug with eye on Rezdiffra combo potential
Endpoints News 8 ene 2026 French biotech Enodia gets €20.7M aided by Pfizer for protein degrader work
FierceBiotech 9 dic 2025 Pfizer continues renewed obesity push with $150M upfront for Fosun unit's GLP-1 drug